Coherus Oncology to release Q1 2026 financial results on May 11 with a management webcast.

Coherus Oncology announced it will report its first quarter 2026 financial results after market close on May 11, 2026. The company will hold a conference call and webcast at 5:00 p.m. Eastern Time to discuss the results and provide a business update. Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and ongoing clinical trials for other cancer treatments. Investors can access the webcast and replay via the company’s investor website.